BlackRock Institutional Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

BlackRock Institutional Trust’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$14.2M	Buy	940,753 +104,002	+12%	+$1.47M	﹤0.01%	2195
2016 Q3	$12.8M	Buy	836,751 +48,008	+6%	+$1.94M	﹤0.01%	2187
2016 Q2	$30.6M	Buy	788,743 +67,349	+9%	+$2.42M	0.01%	1557
2016 Q1	$20.1M	Buy	721,394 +35,196	+5%	+$1.17M	﹤0.01%	1831
2015 Q4	$36.9M	Buy	686,198 +135,440	+25%	+$6.83M	0.01%	1449
2015 Q3	$22.1M	Buy	550,758 +35,069	+7%	+$1.14M	﹤0.01%	1772
2015 Q2	$16.5M	Buy	515,689 +54,965	+12%	+$1.39M	﹤0.01%	2056
2015 Q1	$11M	Buy	460,724 +275,467	+149%	+$6.17M	﹤0.01%	2337
2014 Q4	$3.27M	Sell	185,257 -1,204	-0.6%	-$18.8K	﹤0.01%	2904
2014 Q3	$2.56M	Sell	186,461 -13,187	-7%	-$198K	﹤0.01%	2969
2014 Q2	$3.37M	Buy	199,648 +193,554	+3,176%	+$3.2M	﹤0.01%	2952
2014 Q1	$111K	Buy	+6,094	New	+$110K	﹤0.01%	3760

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Institutional Trust's ITCI Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Intra-Cellular Therapies Inc. (ITCI) stake by 12% in Q4 2016, buying an estimated $1.47M and bringing the position to 940,753 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2195.

BlackRock Institutional Trust first reported a position in ITCI in Q1 2014 and has held it in 12 quarters since. The position peaked at $36.9M in Q4 2015. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

BlackRock Institutional Trust held 940,753 shares of Intra-Cellular Therapies Inc. worth $14.2M as of Q4 2016.
BlackRock Institutional Trust bought 104,002 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $1.47M.
Intra-Cellular Therapies Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2195 holding.
BlackRock Institutional Trust first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Intra-Cellular Therapies Inc. position peaked at $36.9M in Q4 2015.
129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.